Efficacy of the Systane iLux Thermal Pulsation System for the Treatment of Meibomian Gland Dysfunction After 1 Week and 1 Month: A Prospective Study.

OBJECTIVES: To assess 1-week and 1-month efficacy of Systane iLux thermal pulsation treatment for meibomian gland dysfunction (MGD). METHODS: This prospective, nonrandomized, open-label, multicenter study enrolled 30 adult patients (60 eyes) who had a Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire score greater than 6 and total meibomian gland secretion (MGS) score equal to or less than 12 in each eye. All participants received thermal pulsation treatment bilaterally. Primary efficacy measures included MGS score (sum of grades for 15 glands graded on a scale of 0-3; 0 [no secretion], 1 [inspissated], 2 [cloudy], and 3 [clear liquid]) and tear breakup time (TBUT). Secondary efficacy measures were SPEED and Ocular Surface Disease Index (OSDI) scores. RESULTS: The mean age of patients was 52.9±11.9 years. After 1 week, the mean MGS score improved significantly from 4.1±3.1 to 15.8±7.1 (right eye, OD) and 3.7±3.1 to 16.7±7.6 (left eye, OS); mean TBUT improved significantly from 4.9±4.1 to 8.4±3.6 (OD) and 5.2±4.2 to 8.9±3.9 (OS); and mean SPEED and OSDI scores improved significantly from 16.1±5.3 to 7.2±6.1 and 45.2±21.3 to 19.0±16.8, respectively (all P<0.001). After 1 month, the mean MGS score improved to 18.3±8.2 (OD) and 18.6±7.3 (OS); mean TBUT improved to 9.7±3.8 (OD) and 9.6±3.5 (OS); and mean SPEED and OSDI scores improved to 7.0±5.6 and 16.7±14.5, respectively (all P<0.001). No adverse events were reported. CONCLUSIONS: Systane iLux thermal pulsation treatment for MGD resulted in a statistically significant increase in meibomian gland secretion, improvement in tear film stability, and reduction in dry eye symptoms as early as both 1 week and 1 month.

The Case for Using Hydrogen Peroxide Contact Lens Care Solutions: A Review.

Despite their established disinfection and safety benefits, the use of hydrogen peroxide (H2O2) lens care systems among today's wearers of reusable contact lenses remains low in comparison with multipurpose solution (MPS) use. Multipurpose solution systems, however, present several potential drawbacks that may impact patient outcomes, including the use of chemical preservatives for disinfection, biocompatibility issues, and challenges with respect to lens care compliance. Given their unique composition and mechanism of action, one-step H2O2 systems offer the opportunity to avoid many of the challenges associated with MPS use. This article reviews the evolution of H2O2 lens care systems and examines the current scientific and clinical evidence regarding the relative ease of use, lens and tissue compatibility, disinfection efficacy, and ocular surface safety of H2O2 systems. Evaluation of the available data indicates that in comparison with MPS, one-step H2O2 systems tend to promote more favorable compliance, efficacy, comfort, and ocular surface outcomes for a wide range of contact lens-wearing patients. Based on the current published evidence, the authors recommend that eye care practitioners consider making one-step H2O2 systems their first-line contact lens care recommendation for most wearers of reusable lenses.

Comparative studies of hyaluronan in marketed ophthalmic products.

PURPOSE: Research has indicated that there is a correlation between the molecular weight of hyaluronan or hyaluronic acid (HA) and its biocompatibility/biological functions with high molecular weight HA showing many biological benefits. The purpose of this research was to characterize and compare the molecular weights, molecular weight distributions, and concentrations of HA present in a series of commercially available HA-containing ophthalmic products. METHODS: On-line size-exclusion chromatography with triple detection (SEC-TD) was used to determine the molecular weights and concentration of HA in commercially available products, including marketed contact lens multipurpose solutions and contact lens packaging solutions. Eleven commercially available HA-containing ophthalmic products were characterized by SEC-TD. RESULTS: The weight-average molecular weights of the products tested ranged from 155,000 Daltons (Da) to 1,400,000 Da, the number-average molecular weight of the products ranged from 99,000 to 927,000 Da, and the concentration of HA ranged from 0.003 to 0.15%. CONCLUSIONS: A wide range of HA molecular weights and concentrations were found in the 11 ophthalmic products characterized in the present study. This study is the first reported to characterize HA molecular weights and concentrations in various marketed HA-containing ophthalmic products. Future investigation of the effect of low molecular weight HA on eye is required.

IRIS® Registry (Intelligent Research In Sight) Analysis of the Incidence of Monovision in Cataract Patients with Bilateral Monofocal Intraocular Lens Implantation.

Purpose: To determine the incidence of pseudophakic monovision among patients bilaterally implanted with monofocal intraocular lenses (IOLs) and to characterize the distribution of myopic offsets achieved. Patients and Methods: This retrospective database study included data on patients receiving care from ophthalmologists who contributed to the Academy IRIS® (Intelligent Research In Sight) Registry. Anonymized data were collected, including patient age, ethnicity, procedure data (CPT code, date, laterality), and postoperative manifest refractive spherical equivalent (MRSE) in both eyes implanted with monofocal or monofocal toric IOLs. No data regarding IOL manufacturer, model, or power were collected. One primary outcome measure was the percentage of patients achieving monovision (defined as emmetropia within ±0.25 diopters [D] in one eye and a myopic offset of ≥0.50 D in the fellow eye) among all patients receiving bilateral monofocal IOLs at the time of cataract surgery between January 1, 2016, and September 1, 2019, with at least 90 days of follow-up. Other primary outcomes included the distribution and frequency of myopic offsets (anisometropia) between eyes. Results: Of the 16,765 people receiving bilateral monofocal IOLs within the study period, 4796 (28.6%) achieved emmetropia in at least one eye, as defined by an MRSE within ± 0.25 D. The incidence of monovision among these patients was 34.2% (1638/4796). One-quarter (24.7%; 405/1638) of patients who achieved monovision had a myopic offset between 0.50 and 0.74 D, with more than one-third (35.2%; 576/1638) falling within 0.75-1.24 D and 18.0% within 1.25-1.74 D. A myopic offset ≥1.75 D was observed in 22.1% (362/1638) of patients who achieved monovision. Conclusion: Pseudophakic monovision for presbyopia correction was achieved in ~34% of patients in the IRIS Registry bilaterally implanted with monofocal IOLs, with myopic offsets typically ranging from 0.5 to 1.24 D.

Real-world incidence of monofocal toric intraocular lens repositioning: analysis of the American Academy of Ophthalmology IRIS Registry.

PURPOSE: To determine the 12-month incidence of reoperation to realign 2 commercially available types of implanted monofocal toric acrylic intraocular lenses (IOLs). SETTING: American Academy of Ophthalmology IRIS (Intelligent Research in Sight) Registry. DESIGN: Registry retrospective study. METHODS: Eyes that underwent cataract extraction and were implanted with a TECNIS or AcrySof monofocal toric IOL in 2016 and 2017 were identified. The rate of reoperation for IOL realignment (Current Procedural Terminology code 66825) within 365 days of implantation was determined for each IOL group. Risk factors for repositioning were evaluated using logistic regression modeling. RESULTS: A total of 6482 eyes were implanted with a monofocal toric IOL, including 2013 (31.06%) with a TECNIS and 4469 (68.94%) with an AcrySof IOL. During the first postoperative year, 87 (1.3%) eyes underwent surgical IOL repositioning. The incidence of repositioning was significantly higher (P < .0001) for TECNIS-implanted (3.1%, 62/2013) than for AcrySof-implanted (0.6%, 25/4469) eyes (odds ratio [OR] 5.6; 95% CI, 3.5-8.9). Younger age (OR 0.76; 95% CI, 0.67-0.86 per 5-year increase) was associated with a higher risk for IOL repositioning. CONCLUSIONS: Real-world analysis of U.S. patients in the IRIS Registry revealed that the rate of surgical IOL repositioning was 5 times higher in eyes implanted with TECNIS than with AcrySof monofocal toric IOLs for astigmatic correction at the time of cataract surgery. These findings should be considered when selecting a toric IOL for correction of astigmatism in cataract patients, particularly in younger patients with a higher risk for misalignment requiring repositioning.

Academy IRIS® Registry Analysis of Incidence of Laser Capsulotomy Due to Posterior Capsule Opacification After Intraocular Lens Implantation.

Purpose: Academy IRIS® (Intelligent Research in Sight) Registry was used to determine the incidence of postoperative neodymium-doped yttrium aluminum garnet laser capsulotomy (Nd:YAG) and time to posterior capsular opacification (PCO) diagnosis based on intraocular lens (IOL) type and brand. Methods: This retrospective analysis included eyes implanted with 1 of 2 IOL brands, with ≥365 days of follow-up available in the IRIS Registry, and ≥2 visits within 180 days of surgery. Analyses included Nd:YAG incidence due to PCO within 1 year after surgery by IOL type and brand, mean time to PCO diagnosis, and mean time to Nd:YAG. Results: Of 89,947 eyes after cataract surgery, 24,834 (28%) had PCO diagnosis within 365 days, and 9262 (10%) underwent Nd:YAG; 4.1% of 57,523 eyes with monofocal and 21.2% of 32,424 eyes with diffractive multifocal (MF) or diffractive extended depth of focus (EDOF) IOLs had Nd:YAG. Nd:YAG was 3.2 times more likely in eyes with diffractive MF or diffractive EDOF IOLs versus monofocal. For monofocal IOLs, 3.2% of eyes with AcrySof® and 8.1% of eyes with Tecnis® had Nd:YAG (P<0.0001). For diffractive MF or diffractive EDOF IOLs, 13.0% of eyes with AcrySof and 21.7% of eyes with Tecnis had Nd:YAG (P<0.0001). Nd:YAG risk was 2.4 times higher in eyes with Tecnis versus AcrySof IOLs. Overall, mean time to PCO diagnosis and Nd:YAG was 150.7 and 180.7 days. Mean time to PCO for monofocal versus diffractive MF or diffractive EDOF IOLs was 165.3 versus 139.7 days (P<0.0001). Mean time to Nd:YAG for monofocal versus diffractive MF or diffractive EDOF IOLs was 196.4 versus 175.3 days (P<0.05). Conclusion: Real-world data for AcrySof and Tecnis IOLs revealed lower Nd:YAG rates and longer time to PCO diagnosis and Nd:YAG after monofocal versus diffractive multifocal or diffractive EDOF implantation. Nd:YAG rates were significantly lower with AcrySof versus Tecnis IOLs.

Higher-order aberrations when wearing sphere and toric soft contact lenses.

PURPOSE: To determine the on-eye effect of spherical and toric contact lens design on higher-order aberrations (HOA). METHODS: Thirty eyes (15 subjects) entered a masked, randomized, cross-over study. Each eye was fitted with the spherical and toric lens of the following brands in random order: Acuvue Advance, Biomedics 55, Frequency 55, and SofLens 66. HOAs were measured using the Zywave II Aberrometer over a 6-mm aperture up to fifth order. A linear model accounting for the fixed effect of lens type and random effects of subject and eye was created. Paired t-tests were completed between lens brands within the spherical and toric lenses and between the spherical and toric lens within each brand. Best-corrected visual acuity (VA) was measured and compared. RESULTS: No clinically meaningful differences in total HOAs were found between brands or between the spherical and toric lens within a brand. Positive spherical aberration (SA) was reduced by all spherical and toric lenses compared to wearing no lens by 0.07 to 0.23 microm (p < 0.0001). Frequency toric induced the greatest change in SA. The thin-zone design lens (Acuvue Advance for Astigmatism) had a statistically different amount of vertical coma (-0.04 microm) than the three prism-balast toric lenses (0.11 to 0.23 microm; p < 0.0001). SofLens toric had the greatest amount of vertical coma, but better VA than Acuvue Advance for Astigmatism and Frequency toric. With the exception of Acuvue Advance for Astigmatism, toric lenses had greater absolute magnitude of vertical coma than their sphere counterparts (all p < 0.002). No other significant HOA differences were observed. CONCLUSIONS: Toric contact lenses with prism-ballast designs demonstrated more vertical coma, but better VA. Positive SA was reduced by spherical and toric contact lenses. The visual quality effect of lens design and material on induced HOAs warrants further investigation.

Assessing a modified fitting approach for improved multifocal contact lens fitting.

PURPOSE: To compare the effectiveness of a modified and previous fitting guide for multifocal (MF) contact lenses that share a common optical design, lotrafilcon B, nelfilcon A, and delefilcon A, in current soft contact lens (CL) wearers needing presbyopia correction. METHODS: This international multicenter, prospective, randomized, subject-masked study assessed the superiority of the modified guide relative to the previous guide as determined by the number of MF CLs needed to successfully fit each eye at the screening/fitting visit. RESULTS: A total of 183 presbyopic subjects were randomized to fitting using the modified (n = 99) and previous (n = 84) MF CL fitting guides. The mean ±â€¯SD numbers of lenses required to fit each eye at the screening/fitting visit using the modified and previous fitting guides were 1.2 ±â€¯0.5 and 1.4 ±â€¯0.5, respectively. The least-squares mean difference (0.2) met predetermined criteria for superiority of the modified fitting guide. At the screening/fitting visit, 82.8% (164/108) and 65.1% (105/166) of presbyopic eyes were fit with one pair of MF lenses using the modified and previous guides, respectively, and 98.0% (194/198) of eyes were fit with 1-2 pairs of MF lenses using the modified guide. A higher percentage of eye care practitioners gave the highest ratings for ease of fit for the modified than for the previous fitting guide (63.6% [7/11] vs 33.3% [3/9]). CONCLUSIONS: The modified fitting guide was superior at reducing the number of MF lenses required to successfully fit each presbyopic patient.

Comparative performance of the Zyoptix XP and Hansatome zero-compression microkeratomes.

PURPOSE: To compare flap parameters produced by the Zyoptix XP and Hansatome microkeratomes (both Bausch & Lomb) and to evaluate preoperative variables contributing to flap thickness variation. SETTING: Private practice, St. Louis, Missouri, USA. METHODS: Flap dimensions in 75 eyes that prospectively had laser in situ keratomileusis using the Zyoptix XP microkeratome were compared with a historical control sample of 75 eyes treated with the Hansatome microkeratome. The 2 groups were matched for mean keratometry, central corneal pachymetry, spherical equivalent (SE), age, and microkeratome head size and suction ring diameter. RESULTS: The mean ultrasound-measured flap thickness was 126.54 microm +/- 14.6 (SD) and 143.74 +/- 15.0 microm for the 120 microm and 140 microm Zyoptix XP heads, respectively, and 128.90 +/- 20.4 microm and 143.32 +/- 21.0 microm for the 160 microm and 180 microm Hansatome heads, respectively. The standard deviation in flap thickness was smaller and statistically significant for the Zyoptix XP (+/-14.8 microm) versus the Hansatome (+/-20.7 microm) (P = .0039, F test). Preoperative pachymetry and SE (P<.001) accounted for 20% of the variability in measured flap thickness using the Hansatome. For the Zyoptix XP, preoperative pachymetry was statistically significant in explaining the variation in flap thickness with the 120 microm head (P = .02) but not with the 140 microm head. Variation in flap thickness from either Zyoptix XP head was not statistically related to the preoperative SE. CONCLUSION: Although the 2 microkeratomes produced flaps of similar mean thickness, the Zyoptix XP showed significantly less variation in flap thickness than the Hansatome, was less affected by measurable preoperative variables such as SE, and was closer to nominal labeling.

Effects of Polyhexamethylene Biguanide and Polyquaternium-1 on Phospholipid Bilayer Structure and Dynamics.

Multipurpose solutions (MPS) are a single solution that functions to simultaneously rinse, disinfect, clean, and store soft contact lenses. Several commercial MPS products contain polyhexamethylene biguanide (PHMB) and/or polyquaternium-1 (PQ-1) as antimicrobial agents. In this paper we have created an in vitro small unilamellar vesicle (SUV) model of the corneal epithelial surface, and we have assessed the interactions of PHMB and PQ-1 with several model biomembranes by using fluorescence spectroscopy, dynamic light scattering (DLS), and liquid chromatography-mass spectrometry (LC-MS). Steady-state and time-resolved fluorescence were used to assess the membrane acyl chain and polar headgroup region local microenvironment as a function of added PHMB or PQ-1. DLS was used to detect and quantify SUV aggregation induced by PHMB and PQ-1. LC-MS was used to determine the liposomal composition from any precipitated materials in comparison to the as-prepared SUVs. The results are consistent with PHMB adsorbing onto and PQ-1 intercalating into the biomembrane structure. The differences between the two interaction mechanisms have substantial impacts on the biomembrane dynamics and stability.

Reducing dropout of contact lens wear with Biotrue multipurpose solution.

PURPOSE: To evaluate whether the use of Biotrue multipurpose solution (MPS) could significantly reduce the likelihood with which patients drop out of using daily wear contact lenses (CLs) amongst 18-44-year-old frequent replacement CL wearers. METHODS: Daily wear CL subjects habitually using MPSs (other than Biotrue MPS) who reported an intent to imminently drop out of CL wear because of comfort and dryness complaints were recruited to participate in this investigation. Subjects were switched to Biotrue MPS and continued to use habitual CL types with the new MPS for 2 weeks. Subjects completed an online satisfaction questionnaire at baseline and after 2 weeks to assess the change in symptoms and the intent to drop out of CL wear. Six months after completion of the initial study, a follow-up survey was administered to a subset of the initial participants. RESULTS: A total of 153 daily wear (silicone hydrogel and hydrogel) subjects completed this 2-week study with Biotrue MPS. When measuring those with the highest propensity to drop out of lens wear (n=93) after switching to Biotrue MPS, 90% of subjects significantly reduced their likelihood of dropping out of CL wear (P<0.0001). Online interviews were conducted with 73 of the study participants 6 months after completion of the initial study. A total of 93% of participants responded that they were still wearing CLs at least once per week. Of the 7% of respondents who were not currently wearing lenses 6 months after the initial study, two had dropped out of lens wear completely, and three still wore lenses less than once per week. CONCLUSION: Patients intending to drop out of CL wear due to discomfort and dryness significantly reduced their propensity of discontinuing lens wear following use of Biotrue MPS. Six months after completion of the study, 93% of patients were still wearing CLs at least once per week.

Meta-analysis of the ocular biocompatibility of a new multipurpose lens care system.

BACKGROUND: The purpose of this paper is to evaluate the biocompatibility of a novel multipurpose solution (MPS) with a dual disinfectant system containing polyaminopropyl biguanide and polyquaternium-1 (Biotrue®) by analysis of biomicroscopy signs and adverse events in six large clinical trials. METHODS: Data from six consecutive, prospective clinical trials conducted from February 2008 to March 2010 were combined for meta-analysis. Subjects used the new MPS daily for periods of 2 weeks to 6 months. Slit-lamp signs were graded at each follow-up visit using an ordinal scale (0, one; 1, trace; 2, mild; 3, moderate; 4, severe). Analysis for biocompatibility included tracking of greater than grade 2 slit-lamp findings and number of adverse events. RESULTS: A total of 1,567 subjects (3,134 eyes) and 81 clinical investigators participated in the six studies, with 1,499 subjects completing the studies. Based on subject days in the studies, there were 72,904 exposures to the MPS and 7,212 biomicroscopy examinations. The completion rate for the studies was 96.3%. Per observation incidence of any finding greater than grade 2 at the follow-up visits were: corneal staining 0.08%, limbal injection 0.04%, bulbar injection 0.04%, tarsal conjunctiva abnormality 0.09%, and neovascularization 0.01%. There were no other slit-lamp signs greater than grade 2 and no statistically significant difference between hydrogels and silicone hydrogels for any finding. There were no reports of adverse events during the trials. CONCLUSION: Analysis of over 72,000 daily exposures and 7,212 eye examinations showed that the novel MPS exhibited excellent biocompatibility in subjects using daily wear hydrogel or silicone hydrogel lenses.

Tear cytokine response to multipurpose solutions for contact lenses.

PURPOSE: An increased risk of corneal infiltrative events has been noted with the use of certain contact lenses and multipurpose solutions (MPS). This study was designed to evaluate tear cytokine assay as a sensitive, objective, and quantitative measure of the ocular surface response to contact lens/MPS and to consider the assay's clinical relevance in the context of other measures of ocular surface response. METHODS: Two MPS, ReNu® Fresh™ (RNF) and Opti-Free® RepleniSH (OFR), were used with daily wear silicone hydrogel contact lenses in a randomized, prospective crossover study involving 26 subjects. Clinical data collection (conjunctival hyperemia, ocular surface sensitivity, solution induced corneal staining (SICS) test score, and subjective responses) and tear cytokine assays were conducted masked. Responses were tracked as change from baseline throughout the experimental schedule. RESULTS: SIMILAR RESPONSE PATTERNS FOR SEVERAL INFLAMMATORY CYTOKINES WERE SEEN THROUGHOUT BOTH PHASES: subjects who received OFR in Phase I had mean tear concentrations that were generally higher than those of the RNF Phase I group. OFR Phase I subjects had significant (P < 0.01) increases over baseline at day 1 and/or following washout for 13 cytokines (cc chemokine ligands [CCL] 3, CCL5, CCL11, granulocyte-macrophage colony-stimulating factor [GM-CSF], interferon [INF]-γ, interleukin [IL]-2, IL-4, IL-5, IL-6, IL-13, IL-15, IL-17, tumor necrosis factor [TNF]-α). These changes were not observed in RNF Phase I subjects, even though SICS test scores increased. Phase I OFR subjects also had increased dryness, while RNF Phase I subjects had decreased bulbar hyperemia. No changes were detected with respect to limbal hyperemia or surface sensitivity thresholds. CONCLUSION: The tear cytokine assay can detect and differentiate contact lens/MPS induced increases in inflammatory cytokines. Changes in cytokine levels were consistent with measurement of hyperemia and dryness but not with SICS scores, thereby suggesting a proinflammatory response to OFR compared to RNF that is not related to SICS test score. Tear cytokine profiles may be useful for reconciling clinical relevance of test results and in revealing signaling involved in the development of corneal infiltrative events.

A preservative-and-fluorescein interaction model for benign multipurpose solution-associated transient corneal hyperfluorescence.

PURPOSE: Multipurpose contact lens solution (MPS)/preservative-associated transient corneal hyperfluorescence has been suggested to represent corneal injury. To determine the validity of this assumption, the molecular-level interactions of common disinfectants in soft contact lens MPS and the corneal epithelium using an in vitro model were assessed. METHODS: A liposome-based model of the corneal epithelial surface was developed and used to assess the interactions of polyhexamethylene biguanide (PHMB), polyquaternium-1 (PQ-1), and fluorescein with membrane components and the effects of PHMB and PQ-1 on membrane integrity. The fluorescence anisotropy (a measure of interactions between molecules) was determined. Liposome integrity was assessed by measuring the liposome melting point temperature. RESULTS: Free fluorescein did not associate with the liposome (P>0.4). Both fluorescein-tagged PHMB and PQ-1 associated with liposomes (P<0.002 and P≤0.01, respectively); however, only PHMB induced free fluorescein association with membrane components. At physiological temperature, no significant shift in the melting point temperature was observed when liposomes were exposed to PHMB from 0 to 100 ppm (P>0.05). In contrast, exposure of >7 ppm PQ-1 disrupted the liposomes. CONCLUSIONS: Based on this study, PHMB-to-liposome bilayer interaction is nondestructive, even at concentrations 100 times higher than found in commercially available MPS products. In contrast, PQ-1-to-liposome bilayer interaction led to liposome disruption. This study presents molecular-level evidence to support that preservative-associated transient corneal hyperfluorescence is a benign transient phenomenon and its evaluation clinically may be an ambiguous strategy for determining biocompatibility and cell surface integrity.

Assessment of patient and practitioner satisfaction with Biotrue™ multi-purpose solution for contact lenses.

PURPOSE: Consumer product companies often use in-home studies to gain consumer insights on product performance. Satisfaction surveys completed in the office have been shown to overestimate satisfaction ratings. The purpose of this study was to evaluate the consumer acceptance of a novel multi-purpose solution (Bausch & Lomb Biotrue multi-purpose solution) through the use of a unique Internet survey and a measurement of practitioner satisfaction through in-office evaluations. METHODS: Contact lens users were converted to an unbranded, investigational-labeled Biotrue multi-purpose solution. Independent practitioners from 15 investigational sites enrolled patients. Following 7 days of use, subjects completed an Internet survey to capture their perspectives regarding the product. After 2 weeks of use, the investigators exited the subjects. RESULTS: Of the 300 subjects enrolled, 291 (97%) completed the Internet survey. Ninety percent rated Biotrue multi-purpose solution "excellent," "very good," or "good" for overall opinion. Significantly more subjects rated Biotrue multi-purpose solution better than their habitual product. Use of Biotrue multi-purpose solution did not affect the fitting characteristics (centration/movement) or surface wetting of the lens. Throughout the evaluation, there were no adverse events reported. Slit lamp examinations revealed that 99.2% of eyes had minimal findings (no findings or trace or mild findings). With 600 eyes enrolled in the study, practitioners agreed that 95.2% of the eyes appeared healthy throughout the study. CONCLUSIONS: Use of Internet surveys can be an effective method to gain patient perspectives regarding new products dispensed by eye care practitioners. There was a high level of satisfaction with Biotrue multi-purpose solution.

Visual acuity with spherical and toric soft contact lenses in low- to moderate-astigmatic eyes.

PURPOSE: To evaluate the visual acuity of myopic, astigmatic eyes, with spherical and toric soft contact lenses. METHODS: A randomized, masked, cross-over study was conducted to compare acuity with soft spherical and toric contact lenses on patients with between -0.75 and -2.00 D of refractive astigmatism. A total of 15 patients (30 eyes) were fitted with four brands of spherical and toric lenses (Acuvue Advance, Biomedics 55, Frequency 55, and SofLens 66), in random order. An initial visit was conducted to fit the lenses and an over-refraction (OR) was performed to determine the best prescription. At the measurement visit, patients' pupils were dilated with 1.0% tropicamide and 2.5% phenylephrine to allow wavefront aberration measurements, and a final OR was performed. A 6-mm aperture was held in front of the eye to measure visual acuity through just the contact lens and the contact lens with the final OR. Acuity was measured monocularly, under photopic and mesopic conditions with high- and low-contrast logMAR charts at distance. Differences in acuity were analyzed using repeated measures analysis of variance. RESULTS: Visual acuity with soft spherical contact lenses was not significantly different between lens brands. For toric contact lenses, acuity was significantly better with Biomedics 55 and SofLens 66 than with Acuvue Advance; and acuity with SofLens 66 was significantly better than with Frequency 55. Low-astigmatic eyes gained between 3 and 5.5 letters of acuity with toric contact lenses vs. spherical lenses; and moderate-astigmatic eyes gained between 8 and 12.5 letters. CONCLUSIONS: Both low- and moderate-astigmatic eyes showed improvements in acuity with toric contact lenses. Lens brand had a measurable effect on acuity for toric contact lenses. Further investigation of aberrations induced by contact lens design is warranted to explain the observed differences in visual performance.